

Josep Gomez-Lara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2265754/publications.pdf>

Version: 2024-02-01

120
papers

2,693
citations

186254

28
h-index

206102

48
g-index

129
all docs

129
docs citations

129
times ranked

2616
citing authors

#	ARTICLE	IF	CITATIONS
1	Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. <i>European Heart Journal</i> , 2022, 43, 1320-1330.	2.2	26
2	Usefulness of Impella support in different clinical settings in cardiogenic shock.. <i>Journal of Geriatric Cardiology</i> , 2022, 19, 115-124.	0.2	2
3	Amphilimus-versus everolimus-eluting stents in patients with diabetes mellitus: 5-year follow-up of the RESERVOIR trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.8	0
4	Stent thrombosis with new-generation drug-eluting stents: a decade of reassuring evidence. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.6	0
5	Continuous Thermodilution Method to Assess Coronary Flow Reserve. <i>American Journal of Cardiology</i> , 2021, 141, 31-37.	1.6	13
6	Longitudinal Neointimal Distribution Pattern After Everolimus-Eluting Stent Implantation: Insights From Optical Coherence Tomography Study. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 17-23.	0.8	2
7	Target lesion revascularisation of bioresorbable metal scaffolds: a case series study and literature review. <i>EuroIntervention</i> , 2021, 16, 1100-1103.	3.2	8
8	Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 1013-1022.	0.6	4
9	Long-term clinical, angiographic, and optical coherence tomography findings of Mg-based bioresorbable scaffold in patients with acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E69-E77.	1.7	3
10	Early coronary healing in ST segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 673-680.	0.7	3
11	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1165-1178.	2.8	32
12	Funci3n endotelial y microvascular distal a stents farmacoactivos sin pol3mero y captadores de c3lulas endoteliales. Estudio aleatorizado FUNCOMBO. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 1014-1023.	1.2	2
13	Impact of diabetes mellitus on vascular healing process after everolimus-eluting stent implantation: An optical coherence tomography study. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.8	1
14	Importancia de la ateromatosis no obstructiva en pacientes con infarto agudo. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 901-904.	1.2	0
15	Coronary microvascular dysfunction assessed by continuous intracoronary thermodilution: A comparative study with index of microvascular resistance. <i>International Journal of Cardiology</i> , 2021, 333, 1-7.	1.7	12
16	Importance of nonobstructive atheromatosis in patients with acute myocardial infarction. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 901-904.	0.6	0
17	Long-term vascular function in CTO recanalization: A randomized clinical trial of ticagrelor vs. clopidogrel. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.8	0
18	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. <i>PLoS ONE</i> , 2021, 16, e0255263.	2.5	12

#	ARTICLE	IF	CITATIONS
19	First-in-Man Evaluation of a Sirolimus-Eluting Stent With Abluminal Fluoropolymeric/Triflusal Coating With Ultrathin Struts by OCT at 9 Months' Follow-Up: The PROMETHEUS Study. <i>Cardiovascular Revascularization Medicine</i> , 2021, 32, 18-24.	0.8	2
20	Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. <i>Journal of the American Heart Association</i> , 2021, 10, e022123.	3.7	4
21	TCT CONNECT-204 Volumetric Quantification of Absolute Coronary Flow to Assess Flow Reserve. <i>Journal of the American College of Cardiology</i> , 2020, 76, B86-B87.	2.8	0
22	Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease. <i>Thrombosis Research</i> , 2020, 196, 215-221.	1.7	1
23	Optical Coherence Tomography for the Diagnosis of Exercise-Related Acute Cardiovascular Events and Inconclusive Coronary Angiography. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-10.	1.2	3
24	Response by Ortega-Paz et al to Letter Regarding Article, "Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial". <i>Circulation</i> , 2020, 141, e748-e749.	1.6	0
25	REAL-WORLD DATA FROM A MULTICENTER REGISTRY OF CORONARY LITHOTRIPSY FOR TREATMENT OF CALCIFIED CORONARY LESIONS. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1233.	2.8	0
26	Coronary lithoplasty for calcified lesions: real-world multicenter registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 1003-1010.	0.6	4
27	Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design. <i>American Heart Journal</i> , 2020, 222, 174-182.	2.7	7
28	Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial. <i>EuroIntervention</i> , 2020, 16, e155-e163.	3.2	7
29	Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. <i>EuroIntervention</i> , 2020, 15, 1436-1443.	3.2	13
30	Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. <i>EuroIntervention</i> , 2020, 16, e913-e921.	3.2	16
31	Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2019, 140, 1904-1916.	1.6	74
32	Letter by Romaguera et al Regarding Article, "Newer Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: Meta-Analysis of Randomized Trials". <i>Circulation</i> , 2019, 139, 2081-2082.	1.6	0
33	MAGnesium-Based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 64-70.	1.7	10
34	Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloon-expandable and self-expanding valves. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1344-1351.	1.7	11
35	Bioresorbable vascular scaffolds in coronary chronic total occlusions: clinical, vasomotor and optical coherence tomography findings at three-year follow-up (ABSORB-CTO study). <i>EuroIntervention</i> , 2019, 15, 99-107.	3.2	6
36	In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 917-925.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) Tj ETQq1 1 0.784314 rgBT /Overl Cardiology, 2018, 121, 1039-1045.	1.6	10
38	Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists. JACC: Cardiovascular Interventions, 2018, 11, e15-e16.	2.9	3
39	Hallazgos por IVUS en trombosis de stent tard�a y muy tard�a. Comparaci�n entre stents met�licos y farmacoactivos. Revista Espan�la De Cardiolog�a, 2018, 71, 335-343.	1.2	1
40	TlcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER�BVS trial): Rationale and study design. Catheterization and Cardiovascular Interventions, 2018, 91, 1-6.	1.7	6
41	IVUS Findings in Late and Very Late Stent Thrombosis. A Comparison Between Bare-metal and Drug-eluting Stents. Revista Espan�la De Cardiolog�a (English Ed), 2018, 71, 335-343.	0.6	8
42	Evaluaci�n del efecto sin�rgico de la metformina y los inhibidores mTOR sobre la endotelizaci�n de los stents farmacoactivos en pacientes diab�ticos. Revista Espan�la De Cardiolog�a, 2018, 71, 917-925.	1.2	2
43	Long-Term Coronary Functional Assessment of the Infarct-Related Artery�Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents. JACC: Cardiovascular Interventions, 2018, 11, 1559-1571.	2.9	29
44	One-year optical coherence tomography findings in patients with late and very-late stent thrombosis treated with intravascular imaging guided percutaneous coronary intervention. International Journal of Cardiovascular Imaging, 2018, 34, 1511-1520.	1.5	6
45	Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. American Heart Journal, 2018, 204, 205-209.	2.7	4
46	Association between coronary atherosclerosis progression and in-stent neoatherosclerosis in patients with ST-elevation myocardial infarction at five-year follow-up. EuroIntervention, 2018, 14, 206-214.	3.2	3
47	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention, 2018, 13, 1939-1945.	3.2	7
48	Invasive strategy and frailty in very elderly patients with acute coronary syndromes. EuroIntervention, 2018, 14, e336-e342.	3.2	46
49	Temporal trends in frequency, management and outcomes of coronary perforations. Minerva Cardiology and Angiology, 2018, 66, 361-367.	0.7	1
50	Long-term prognostic impact of non-invasive follow-up with computed tomography angiography in patients with left main coronary artery stenting. Minerva Cardioangiologica, 2018, 66, 528-535.	1.2	3
51	Mechanisms of Very Late Bioresorbable�Scaffold Thrombosis. Journal of the American College of Cardiology, 2017, 70, 2330-2344.	2.8	117
52	Early Collapse of a Magnesium�Bioresorbable Scaffold. JACC: Cardiovascular Interventions, 2017, 10, e171-e172.	2.9	14
53	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. International Journal of Cardiology, 2016, 214, 483-484.	1.7	20
54	Five-Year Optical Coherence Tomography in Patients With ST-Segment�Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	22

#	ARTICLE	IF	CITATIONS
55	Noninvasive Follow-Up of Patients With Spontaneous Coronary Artery Dissection With CT Angiography. JACC: Cardiovascular Imaging, 2016, 9, 896-897.	5.3	79
56	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 2016, 9, 42-50.	2.9	68
57	IVUS-guided treatment strategies for definite late and very late stent thrombosis. EuroIntervention, 2016, 12, e1355-e1365.	3.2	14
58	Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2015, 85, E116-22.	1.7	8
59	Impact of Anaemia on Mortality and its Causes in Elderly Patients with Acute Coronary Syndromes. Heart Lung and Circulation, 2015, 24, 557-565.	0.4	20
60	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. JACC: Cardiovascular Interventions, 2015, 8, 189-197.	2.9	145
61	Preserved endothelial vasomotor function after everolimus-eluting stent implantation. EuroIntervention, 2015, 11, 643-649.	3.2	14
62	Coronary perforation after bioresorbable vascular scaffold implantation. EuroIntervention, 2015, 10, e1-e2.	3.2	3
63	Reproducibility of intravascular ultrasound iMAP for radiofrequency data analysis: Implications for design of longitudinal studies. Catheterization and Cardiovascular Interventions, 2014, 83, E233-42.	1.7	10
64	Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation. Journal of Cardiovascular Translational Research, 2014, 7, 39-46.	2.4	18
65	Clinical Impact of Intravascular Ultrasound Guidance in Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Disease. JACC: Cardiovascular Interventions, 2014, 7, 244-254.	2.9	209
66	Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2014, 7, 315-324.	2.9	108
67	Prognostic Impact of Chronic Total Occlusion in a Nonculprit Artery in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. Revista Espanola De Cardiologia (English Ed), 2014, 67, 359-366.	0.6	7
68	Valor pronóstico de la oclusión total crónica de una arteria no responsable en el infarto agudo de miocardio tratado con angioplastia primaria. Revista Espanola De Cardiologia, 2014, 67, 359-366.	1.2	3
69	Lumen enlargement of the coronary segments located distal to chronic total occlusions successfully treated with drug-eluting stents at follow-up. EuroIntervention, 2014, 9, 1181-1188.	3.2	33
70	Longitudinal deformation of drug-eluting stents: evaluation by multislice computed tomography. Journal of Invasive Cardiology, 2014, 26, 161-6.	0.4	7
71	Polymer-free amphilimus-eluting stents in patients with diabetes mellitus. Minerva Cardioangiologica, 2014, 62, 421-6.	1.2	2
72	CoreValve® Aortic Bioprosthesis Implantation in a Patient With Situs Inversus Totalis With Dextrocardia. Revista Espanola De Cardiologia (English Ed), 2013, 66, 409-410.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Reproducibility of qualitative assessment of stent struts coverage by optical coherence tomography. International Journal of Cardiovascular Imaging, 2013, 29, 5-11.	1.5	16
74	Implante de bioprótesis aórtica CoreValve® en un paciente con situs inversus totalis con dextrocardia. Revista Española De Cardiología, 2013, 66, 409-410.	1.2	3
75	Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction. American Heart Journal, 2013, 166, 119-126.e1.	2.7	5
76	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 168, 2632-2636.	1.7	11
77	Three-dimensional optical frequency domain imaging in conventional percutaneous coronary intervention: the potential for clinical application. European Heart Journal, 2013, 34, 875-885.	2.2	54
78	Multislice CT for assessing in-stent dimensions after left main coronary artery stenting: a comparison with three dimensional intravascular ultrasound. Heart, 2013, 99, 1106-1112.	2.9	11
79	MGuard Mesh-Covered Stent for Treatment of ST-Segment Elevation Myocardial Infarction with High Thrombus Burden Despite Manual Aspiration. Journal of Interventional Cardiology, 2013, 26, 1-7.	1.2	11
80	Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. Thrombosis and Haemostasis, 2013, 110, 110-117.	3.4	19
81	Global risk score for choosing the best revascularization strategy in patients with unprotected left main stenosis. Journal of Invasive Cardiology, 2013, 25, 650-8.	0.4	5
82	Analysis of 1-year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2012, 28, 1307-1314.	1.5	13
83	Long-term Follow-up After Percutaneous Treatment of the Unprotected Left Main Stenosis in High Risk Patients Not Suitable for Bypass Surgery. Revista Española De Cardiología (English Ed), 2012, 65, 530-537.	0.6	0
84	Impacto en tiempos de actuación y perfil de los pacientes tratados con angioplastia primaria en el Área metropolitana sur de Barcelona al implantar el programa Código Infarto. Revista Española De Cardiología, 2012, 65, 911-918.	1.2	42
85	Impact on Delay Times and Characteristics of Patients Undergoing Primary Percutaneous Coronary Intervention in the Southern Metropolitan Area of Barcelona After Implementation of the Infarction Code Program. Revista Española De Cardiología (English Ed), 2012, 65, 911-918.	0.6	6
86	Seguimiento a largo plazo tras el tratamiento percutáneo del tronco coronario izquierdo no protegido en pacientes de alto riesgo no aptos para cirugía de revascularización. Revista Española De Cardiología, 2012, 65, 530-537.	1.2	9
87	Endothelial Function in Coronary Chronic Total Occlusions. Journal of the American College of Cardiology, 2012, 60, 871-872.	2.8	2
88	Endothelial and Smooth Muscle Cells Dysfunction Distal to Recanalized Chronic Total Coronary Occlusions and the Relationship With the Collateral Connection Grade. JACC: Cardiovascular Interventions, 2012, 5, 170-178.	2.9	39
89	Distance of Lipid Core-Rich Plaques From the Ostium by NIRS in Nonculprit Coronary Arteries. JACC: Cardiovascular Imaging, 2012, 5, 297-299.	5.3	9
90	Agreement and reproducibility of grayscale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 890-902.	1.7	29

#	ARTICLE	IF	CITATIONS
91	Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 880-888.	1.7	38
92	Morphology of coronary artery lesions assessed by virtual histology intravascular ultrasound tissue characterization and fractional flow reserve. International Journal of Cardiovascular Imaging, 2012, 28, 221-228.	1.5	19
93	Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. International Journal of Cardiovascular Imaging, 2012, 28, 499-511.	1.5	16
94	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2012, 79, 219-228.	1.7	46
95	Comparison of plaque prolapse in consecutive patients treated with Xience V and Taxus Liberte stents. International Journal of Cardiovascular Imaging, 2012, 28, 23-31.	1.5	10
96	Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention, 2012, 8, 214-224.	3.2	51
97	Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial. EuroIntervention, 2012, 8, 352-358.	3.2	5
98	6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm. Journal of the American College of Cardiology, 2011, 58, 258-264.	2.8	44
99	Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2011, 4, 992-1001.	2.9	75
100	New Insights Into the Coronary Artery Bifurcation. JACC: Cardiovascular Interventions, 2011, 4, 921-931.	2.9	53
101	Serial In Vivo Intravascular Ultrasound-Based Echogenicity Changes of Everolimus-Eluting Bioresorbable Vascular Scaffold During the First 12 Months After Implantation. JACC: Cardiovascular Interventions, 2011, 4, 1281-1289.	2.9	19
102	Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2011, 4, 1271-1280.	2.9	61
103	NIRS and IVUS for Characterization of Atherosclerosis in Patients Undergoing Coronary Angiography. JACC: Cardiovascular Imaging, 2011, 4, 647-655.	5.3	76
104	Assessment of Coronary Atherosclerosis Progression and Regression at Bifurcations Using Combined IVUS and OCT. JACC: Cardiovascular Imaging, 2011, 4, 774-780.	5.3	40
105	3D Reconstructions of Optical Frequency Domain Imaging to Improve Understanding of Conventional PCI. JACC: Cardiovascular Imaging, 2011, 4, 1044-1046.	5.3	5
106	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. American Heart Journal, 2011, 162, 1069-1079.e2.	2.7	16
107	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2011, 27, 859-866.	1.5	21
108	Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheterization and Cardiovascular Interventions, 2011, 78, 3-12.	1.7	134

#	ARTICLE	IF	CITATIONS
109	Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up. JACC: Cardiovascular Interventions, 2011, 4, 789-799.	2.9	48
110	A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. European Heart Journal, 2011, 32, 294-304.	2.2	58
111	Intravascular ultrasound radiofrequency analysis after optimal coronary stenting with initial quantitative coronary angiography guidance: an ATHEROREMO sub-study. EuroIntervention, 2011, 6, 977-984.	3.2	11
112	Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: an ARTS-II sub-study. EuroIntervention, 2011, 6, 1060-1067.	3.2	10
113	Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. EuroIntervention, 2011, 6, 1110-1116.	3.2	16
114	Healing of a coronary artery dissection detected by intravascular ultrasound and optical coherence tomography. EuroIntervention, 2011, 7, 288-289.	3.2	2
115	Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention, 2011, 7, 386-399.	3.2	37
116	CRosser As First choice for crossing Totally occluded coronary arteries (CRAFT Registry): focus on conventional angiography and computed tomography angiography predictors of success. EuroIntervention, 2011, 7, 480-486.	3.2	11
117	A Comparison of the Conformability of Everolimus-Eluting Bioresorbable Vascular Scaffolds to Metal Platform Coronary Stents. JACC: Cardiovascular Interventions, 2010, 3, 1190-1198.	2.9	92
118	Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. International Journal of Cardiology, 2010, 145, 235-237.	1.7	21
119	A comparison of the distribution of necrotic core in bifurcation and non-bifurcation coronary lesions: an in vivo assessment using intravascular ultrasound radiofrequency data analysis. EuroIntervention, 2010, 6, 321-327.	3.2	25
120	The coronary Stent-On-A-Wire (SOAW). EuroIntervention, 2010, 6, 413-417.	3.2	7